Cancer Pain Management (Part 1): Outline & Pharmacotherapy

Author: Dr Shirish P Amatya

Why cancer pain management needs a structured approach

Cancer pain is common, multifactorial, and often changes over time. The most effective management is not a single drug choice—it is a system: careful pain assessment, clear goals, stepwise pharmacotherapy, proactive adverse-effect prevention, and regular reassessment. Most patients achieve meaningful relief when treatment is individualized and titrated rather than under-dosed or changed randomly.

Clinical outline: a practical workflow

Use this simple workflow at every visit (or every day in inpatients):

Confirm the pain mechanism(s): nociceptive (somatic/visceral), neuropathic, mixed, or nociplastic-like features.
Measure severity and pattern: baseline pain, episodic flares, and true breakthrough cancer pain (BTcP).
Identify red flags: spinal cord compression, pathological fracture, bowel obstruction, infection, or hemorrhage.
Check current analgesics: what was tried, what worked, what caused adverse effects, and adherence.
Set goals: pain score target, sleep, function, mobilization, and patient-defined priorities.
Choose stepwise pharmacotherapy (WHO ladder concept) and plan a follow-up interval for titration.
Prevent predictable side effects (constipation, nausea, sedation) before they occur.
Reassess frequently and adjust: escalate, rotate, add adjuvants, or consider interventional options (Part 2).

Pain assessment essentials that directly change prescribing

A short, focused assessment prevents common errors such as treating neuropathic pain with only NSAIDs, or escalating opioids when constipation and anxiety are the dominant drivers. Document:

Location(s), radiation, and quality (burning/shooting suggests neuropathic component).
Intensity (0–10) for baseline pain and for episodes; note timing and triggers.
Functional impact: sleep, ambulation, eating, mood, breathing, and ability to cough.
Cancer treatment status: chemo/radiotherapy, surgery, bone metastasis, mucositis, neuropathy.
Organ function and risk: renal/hepatic impairment, frailty, delirium risk, respiratory disease.
Medication interactions: sedatives, alcohol, serotonergic drugs, anticoagulants, and QT-prolonging agents.

Stepwise pharmacotherapy (WHO ladder logic)

The classic WHO ladder remains a useful framework, but modern practice is more flexible: moderate–severe cancer pain often warrants early strong opioids with adjuvants, while mild pain can respond well to non-opioids. Think in “steps,” but tailor to mechanism, severity, and urgency.

Step 1: Non-opioid analgesics (foundation for many patients)

Non-opioids reduce inflammatory and musculoskeletal pain, and they can lower opioid requirements when used appropriately.

Key options and practical points:

Paracetamol (acetaminophen): useful for mild pain and as an adjunct; consider total daily dose and liver risk.
NSAIDs: particularly helpful for bone pain and inflammatory pain; balance benefit against GI, renal, and cardiovascular risk.
COX-2 selective agents: may reduce GI toxicity but still require caution in cardiovascular disease and renal impairment.
Topicals (selected situations): localized musculoskeletal pain can respond to topical NSAIDs; avoid overpromising in deep cancer pain.

Practical prescribing tip: if NSAIDs are used, define a trial period and a stop rule (e.g., renal function change, GI symptoms, bleeding risk). In bone metastasis pain, combine non-opioids with disease-modifying strategies (radiotherapy, bisphosphonates/denosumab) where appropriate.

Step 2: Opioids for mild–moderate pain (or as a bridge)

In cancer pain, the boundary between “weak” and “strong” opioids is less important than timely relief. If pain is clearly moderate and impacting function, many clinicians move directly to a low-dose strong opioid.

General principles:

Start low, titrate to effect, and reassess quickly (hours to days depending on setting).
Choose immediate-release (IR) for titration; switch to sustained-release (SR) when stable.
Always prescribe a breakthrough/rescue option when baseline opioids are used.
Co-prescribe bowel regimen proactively unless contraindicated.

Step 3: Strong opioids for moderate–severe cancer pain

Strong opioids are central to cancer pain relief. Success depends on choosing an appropriate opioid, titrating correctly, and preventing/handling adverse effects. A “good opioid plan” is written as a regimen: baseline + rescue + side-effect prevention + follow-up.

How to start and titrate opioids (clinician-friendly approach)

A practical titration strategy:

Start with an IR opioid at a low dose appropriate to opioid exposure (opioid-naïve vs opioid-tolerant).
Review response and side effects frequently; increase dose in small, planned steps until adequate relief or toxicity.
Once stable over 24–48 hours, convert to SR/controlled-release for baseline control.
Define rescue dosing for breakthrough pain (commonly a fraction of total daily opioid dose) and document limits.
If escalating doses provide diminishing benefit with rising toxicity, consider opioid rotation or add mechanism-based adjuvants.

Breakthrough cancer pain (BTcP): treat the pattern, not just the number

Breakthrough cancer pain is a transient flare of severe pain that occurs despite otherwise controlled baseline pain. It can be predictable (incident pain with movement) or unpredictable. Effective BTcP management includes both rescue medication and prevention strategies (e.g., pre-emptive dosing before physiotherapy or wound care).

Practical BTcP checklist:

Confirm baseline control: optimize the around-the-clock opioid first.
Identify trigger: movement, procedures, swallowing, bowel movement, cough, dressing changes.
Choose a rescue agent with appropriate onset: IR oral opioids for many; rapid-onset formulations in selected settings.
Educate the patient: when to take rescue, how often, expected onset, and when to call for help.
If rescue is needed repeatedly every day, increase baseline dose or switch to a more suitable regimen.

Adjuvant analgesics (mechanism-based add-ons)

Adjuvants are not “optional extras”—they often provide the missing piece, especially when neuropathic pain, bone pain, spasm, edema, or inflammation drives symptoms. Adding the right adjuvant can reduce opioid dose escalation and improve function.

Neuropathic pain adjuvants

Gabapentinoids: useful for neuropathic components; titrate gradually and watch for sedation, dizziness, and edema.
Antidepressants (selected): can help neuropathic pain and comorbid insomnia/anxiety; consider anticholinergic burden and interactions.
Topical agents (selected): localized neuropathic pain may respond in some patients; avoid unrealistic expectations in deep tumor pain.

Bone metastasis and inflammatory pain adjuvants

NSAIDs/COX-2 inhibitors: often effective but require careful risk assessment.
Corticosteroids (short courses or selected indications): can reduce edema, nerve compression symptoms, and inflammatory pain; monitor glucose, mood, infection risk.
Antiresorptives (as part of oncology care): may reduce skeletal-related events and pain over time.

Visceral pain and colic-like pain

Opioids remain central; consider antispasmodics in appropriate colicky pain patterns.
Treat constipation and bowel dysfunction aggressively—unrecognized opioid-induced constipation can mimic or worsen visceral pain.

Managing predictable opioid adverse effects (do this upfront)

Most opioid “failures” are not analgesic failures—they are preventable adverse effects that lead to nonadherence or dose limitation. Build side-effect prevention into every opioid prescription.

Common adverse effects and practical responses:

Constipation: start stimulant laxative ± stool softener; add osmotic agents if needed; consider peripherally acting agents in refractory cases.
Nausea: often transient; use antiemetics early; review for constipation, vestibular causes, and drug interactions.
Sedation: assess other sedatives, dehydration, renal function; reduce dose, rotate opioid, or adjust regimen if persistent.
Delirium: evaluate infection, dehydration, hypercalcemia, CNS metastasis, and medications; consider opioid rotation and supportive care.
Respiratory depression: uncommon with careful titration; risk rises with rapid escalation, comorbid lung disease, and sedative co-use—monitor and educate.

Opioid rotation and special situations

Opioid rotation is a strategic switch to improve analgesia or tolerability when dose escalation causes unacceptable toxicity. It is particularly useful in renal impairment, neurotoxicity, hallucinations, myoclonus, or refractory nausea. When rotating, apply conservative dose reduction for incomplete cross-tolerance, then titrate to effect.

Also consider these special situations:

Renal impairment: prefer opioids and regimens with safer metabolite profiles; avoid accumulation and monitor sedation/confusion.
Hepatic impairment: start low, go slow; avoid large dose jumps; monitor for delirium.
Elderly/frail patients: lower starting doses, slower titration, and tighter monitoring.
Swallowing difficulty or GI obstruction: consider non-oral routes (transdermal, subcutaneous) based on clinical context.
History of substance use disorder: structured prescribing, clear agreements, and involvement of specialist teams as needed.

Follow-up and documentation: what to record each time

Cancer pain prescribing is safest when it is explicitly documented and routinely reviewed. At each follow-up, record pain scores (baseline and episodic), functional goals, opioid doses (baseline and rescue use), adverse effects, bowel function, sedation level, and any triggers for breakthrough pain.

What’s next (Part 2)

Author: Dr Hari Poudel

Part 2 covers interventional cancer pain management—nerve blocks, neurolytic procedures, intrathecal therapy, vertebral augmentation, sympathetic blocks, and procedure selection based on pain phenotype and disease stage.

When to consider interventional cancer pain procedures

Interventions are not a “last resort,” but they are also not a substitute for good pharmacotherapy. They are best used when pain remains clinically unacceptable despite optimized oral/transdermal medication, or when a specific pain generator can be targeted to reduce suffering, improve function, and lower systemic drug burden.

Typical triggers to escalate to interventions:

Pain refractory to optimized oral/transdermal pharmacological therapy (including appropriate adjuvants).
Intolerable medication adverse effects (sedation, delirium, constipation) limiting dose escalation.
Clearly localized pain amenable to a targeted block (e.g., upper abdominal visceral pain, pelvic tumor pain, perineal pain).
Incident/breakthrough pain that is predictable and procedure-related (movement, coughing, dressing changes).
Structural pain generators where a procedure addresses the cause (e.g., metastatic vertebral fracture treated with vertebral augmentation).
Short life expectancy with high symptom burden where rapid, durable relief is required.

How to choose the right intervention: a practical framework

Intervention selection should be mechanism-based. Ask three questions: (1) What is the dominant pain mechanism (visceral, somatic, neuropathic, mixed)? (2) Where is the pain generator (upper abdomen, pelvis, perineum, chest wall, spine, limb, head/neck)? (3) What is the clinical context (coagulopathy, infection risk, functional status, life expectancy)? This keeps procedures targeted and avoids “shotgun” interventions.

1) Neuraxial analgesia: epidural and intrathecal drug delivery

Neuraxial analgesia is a cornerstone for severe cancer pain when systemic opioids are ineffective or poorly tolerated. Delivery may be epidural or intrathecal. The choice depends on expected duration of therapy, practicality, and patient prognosis.

Patient selection and planning

Consider life expectancy when selecting the system: implantable intrathecal therapy is typically favored when expected survival is longer (often >3 months), while externalized systems may suit shorter horizons or rapidly changing needs.
Confirm that pain is opioid-responsive but dose-limited by toxicity, or that very high systemic doses are required for partial benefit.
Assess bleeding risk, sepsis, spinal anatomy, and ability to manage a device (patient/caregiver support).
Define goals: pain relief at rest and movement, reduced rescue dosing, improved alertness, better sleep.

Catheter placement patterns (epidural)

Epidural catheter level is chosen to match the dermatomal distribution of pain. A practical mapping approach:

Upper thoracic tumors (e.g., Pancoast tumor, brachial plexopathy): high thoracic placement.
Thoracic/rib metastasis, rib fracture pain, pulmonary tumor-related chest wall pain: thoracic placement tailored to pain level.
Upper abdominal pain: lower thoracic placement (often around T8–T12 territory).
Lower abdominal or pelvic pain: lower thoracic to lumbar range depending on dominant distribution.

Common intrathecal medications and practical dosing concepts

Intrathecal therapy commonly uses opioids and selected non-opioid agents to achieve strong analgesia with lower systemic exposure. Typical agents include morphine and, in selected refractory cases, ziconotide. Start with conservative dosing and titrate carefully to balance analgesia and neuropsychiatric effects.

Examples of commonly taught starting ranges (titrate to clinical response):

Intrathecal morphine: often initiated in low daily doses and titrated slowly.
Ziconotide: typically started at very low microgram-per-day doses with cautious titration.

A key safety concept is opioid potency by route: epidural and intrathecal dosing is far more potent than oral dosing. When converting between routes, use conservative conversion factors, reduce for incomplete cross-tolerance, and titrate.

2) Neurolytic and destructive techniques: when reversible is not enough

Destructive interventions aim for longer-lasting relief by interrupting nociceptive pathways. They are reserved for carefully selected patients, typically with advanced disease, severe focal pain, and limited response to other strategies.

Chemical neurolysis (principles)

Chemical neurolysis uses neurolytic agents (commonly alcohol or phenol solutions) to damage pain-transmitting fibers. Alcohol injections can be painful; local anesthetic is often used to reduce injection discomfort. Because neurolysis can cause neuritis, hypotension, and rare but serious neurological injury, meticulous technique and imaging guidance are essential.

3) Targeted plexus and sympathetic blocks for visceral cancer pain

Visceral cancer pain often responds dramatically to targeted sympathetic plexus interventions. These procedures are most valuable when pain is anatomically consistent with a specific plexus distribution.

Coeliac plexus block (upper abdominal visceral pain)

Coeliac plexus interventions are classically used for upper abdominal visceral pain (e.g., pancreatic and other upper abdominal malignancies). They can be diagnostic (local anesthetic) or longer-lasting (neurolytic) depending on patient needs.

Contraindications and safety considerations:

Patient refusal.
Local or systemic sepsis.
Bleeding diathesis/anticoagulation risk that cannot be corrected.

Common procedural approaches (selected by operator experience and anatomy):

Anterocrural and retrocrural approaches.
Transaortic or transdiscal approaches in selected situations.
Anterior or endoscopic approaches in specialized settings.

Complications can be general (bleeding, hematoma, infection, intravascular injection, local anesthetic toxicity) or specific. The most feared rare complication is neurological injury. Risk reduction depends on imaging guidance, aspiration/contrast checks where applicable, and careful patient selection.

Splanchnic nerve radiofrequency ablation (RFA)

Splanchnic RFA is a minimally invasive option for chronic upper abdominal visceral pain when conservative measures fail. It uses heat generated by radiofrequency energy to modulate targeted nerve fibers that carry visceral pain signals.

Where it fits best:

Severe upper abdominal visceral pain refractory to optimized medications.
Patients in whom a more extensive neurolytic procedure is undesirable, or where a staged approach is preferred.

Superior hypogastric plexus block (pelvic tumor pain)

Pelvic malignancies can produce deep visceral pain that is difficult to control with systemic medication alone. A superior hypogastric plexus block targets sympathetic afferents from pelvic organs and can provide meaningful relief.

Clinical cues suggesting benefit:

Visceral pelvic pain (deep, cramping, pressure-like) from pelvic tumors.
Pain that persists despite opioid escalation or causes significant opioid-related toxicity.

Ganglion impar block (perineal, distal pelvic, and coccygeal cancer pain)

The ganglion impar (Walther ganglion) is a sympathetic structure near the sacrococcygeal region. Blocking it can be helpful for perineal pain, distal pelvic pain, and pain around the coccyx and rectal region.

When to consider:

Severe perineal pain from pelvic malignancy.
Rectal, anal, vulvar, or distal pelvic pain with sympathetic features.
Coccygeal pain related to tumor involvement.

4) Cordotomy for unilateral, refractory cancer pain

Cordotomy is a neuroablative procedure that interrupts the spinothalamic tract to relieve severe pain. It is most commonly considered for unilateral pain (often below the neck) in advanced cancer when other strategies fail.

Percutaneous cervical cordotomy (clinical summary)

Best for unilateral refractory pain where rapid, robust relief is required.
Often considered when life expectancy is limited (commonly within about a year in many teaching frameworks), though selection is individualized.
Typically performed percutaneously using image guidance to lesion pain pathways contralateral to the pain.

Because cordotomy can carry serious risks (including motor, sensory, and respiratory complications depending on level and technique), it should be performed only in experienced centers with careful informed consent and post-procedure monitoring.

5) Vertebroplasty and kyphoplasty for metastatic vertebral fractures

Metastatic vertebral compression fractures cause severe axial pain, impaired mobility, and reduced quality of life. Vertebroplasty and kyphoplasty can stabilize the vertebral body and reduce pain, often enabling mobilization and easier caregiving.

Key points:

Both procedures involve percutaneous cement augmentation under imaging guidance.
They have overlapping indications and contraindications; choice depends on anatomy, collapse pattern, and operator preference.
Major complications include infection and cement leakage. Leakage is often asymptomatic but can be dangerous if embolization occurs.

6) Peripheral and regional blocks for focal cancer pain

Not all cancer pain is visceral. Tumor invasion, surgery, radiotherapy, and metastasis can create focal somatic pain that responds well to regional anesthesia techniques. These blocks can be single-shot or continuous catheter-based depending on duration and goals.

Common categories of peripheral/regional blocks used in cancer pain practice:

Paravertebral blocks (e.g., chest wall or unilateral thoracic pain patterns).
Head and face region blocks (selected head/neck cancer pain patterns).
Plexus blocks (e.g., brachial or lumbosacral plexus territory pain in selected cases).
Intercostal blocks (rib metastasis, thoracotomy pain, focal chest wall pain).

These techniques are often “non-destructive”: local anesthetic with or without steroid is deposited or infused to provide reversible conduction block and analgesia. They can be especially valuable when pain is positional or procedure-related, or when systemic therapy is limited by adverse effects.

7) Neuromodulation: peripheral nerve/field stimulation and spinal cord stimulation (selected cases)

Neuromodulation can be considered in selected cancer pain scenarios to modulate nociceptive traffic, particularly when pain has a neuropathic component, or when longer-term symptom control is desired and prognosis allows. Candidate selection is individualized, considering infection risk, coagulation status, and expected trajectory.

Safety checklist before any intervention

Before proceeding, confirm that the benefit outweighs risk in the patient’s current condition. A concise checklist improves outcomes and reduces avoidable complications.

Coagulation: review anticoagulants/antiplatelets and correct reversible coagulopathy.
Infection: rule out local or systemic sepsis; optimize skin preparation and sterile technique.
Imaging and anatomy: understand tumor burden, spinal stability, and procedural pathway.
Functional goals: document what “success” means (sleep, mobility, ability to sit, reduced rescue doses).
Follow-up plan: specify monitoring, dose adjustments, and escalation pathway if relief is incomplete.

FAQ for patients and caregivers

Do nerve blocks cure cancer pain permanently?

They can provide significant relief, sometimes for weeks to months, but cancer pain can evolve. Some blocks are temporary (diagnostic or therapeutic), while neurolytic procedures aim for longer-lasting relief in selected cases.

Is an intrathecal pump only for end-stage cancer?

Not necessarily. It is often considered when pain is severe and systemic medications are ineffective or poorly tolerated. Prognosis, support system, and goals of care guide timing.

What is the difference between vertebroplasty and kyphoplasty?

Both stabilize fractured vertebrae with cement under imaging guidance. Kyphoplasty uses a balloon step in many techniques to create space and may help restore some height in selected fractures.

When is cordotomy considered?

Cordotomy is considered for severe unilateral cancer pain that remains uncontrolled despite optimized medications and less invasive procedures, typically in advanced disease and in specialized centers.